title: Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder.
abstract: RBP-6000 is a novel sustained-release formulation of buprenorphine for the treatment of opioid use disorder, which has been designed for once-monthly (28 days) subcutaneous (SC) injections. A population pharmacokinetic (PK) model was developed to describe the time course of buprenorphine plasma concentrations after repeated SC injections of RBP-6000 at 50 mg, 100 mg, 200 mg, or 300 mg in treatment-seeking opioid-dependent subjects previously on sublingual buprenorphine (Subutex(®) ) treatment. The μ-opioid receptor occupancy was predicted using a previously developed PK/PD Emax model. The results of the population PK analysis jointly with the predicted level of μ-opioid receptor occupancy provided quantitative criteria for clinical dose selection for RBP-6000: the dose of 300 mg every 28 days seems appropriate for immediately achieving an effective exposure after the first SC injection and to maintain effective levels of exposure during chronic treatment. Furthermore, simulations conducted to evaluate the potential impact of a holiday in drug intake indicated that in the unexpected event of a 2-week holiday, levels of μ-opioid receptor occupancy remained consistently above 70% with no significant loss of drug efficacy. This analysis indicated that RBP-6000 has the potential for becoming an effective treatment for opioid-dependent subjects by addressing compliance issues associated with the current once-a-day treatments.
authors.affiliation: Indivior Inc, Richmond, VA, USA.
authors.forename: Celine M
authors.initials: CM
authors.lastname: Laffont
authors.affiliation: R&D Department, Pharmacometrica, Longcol, La Fouillade, France.
authors.forename: Roberto
authors.initials: R
authors.lastname: Gomeni
authors.affiliation: Indivior Inc, Richmond, VA, USA.
authors.forename: Christian
authors.initials: C
authors.lastname: Heidbreder
authors.affiliation: Indivior Inc, Richmond, VA, USA.
authors.forename: J P
authors.initials: JP
authors.lastname: Jones
authors.affiliation: Indivior Inc, Richmond, VA, USA.
authors.forename: Azmi F
authors.initials: AF
authors.lastname: Nasser
mesh_terms: D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002047:Buprenorphine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004339:Drug Compounding; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D009293:Opioid-Related Disorders / Q000188:drug therapy* / Q000378:metabolism*; D017450:Receptors, Opioid, mu / Q000819:agonists / Q000378:metabolism; D055815:Young Adult
chemical_list: D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D017450:Receptors, Opioid, mu; D002047:Buprenorphine
keywords: RBP-6000; clinical effective dose; long-acting buprenorphine; population pharmacokinetic model